Oncogene mutation survey in MPNST cell lines enhances the dominant role of hyperactive Ras in NF1 associated pro-survival and malignancy

Translational Oncogenomics

Volumn 5, Issue , 2012, Pages 1-7

  Sun, Daochun ^a   Tainsky, Michael A ^a   Haddad, Ramsi ^a,b,c  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b KARMANOS CANCER INSTITUTE   (United States)

^c Results Genomics   (Canada)

Author keywords

MPNST; Neurofibromatosis; Oncogene mutation; Ras GAP

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NEUROFIBROMIN;

ARTICLE; BRAF GENE; CANCER CELL CULTURE; CANCER SURVIVAL; CARCINOGENESIS; CHROMOSOME 17; CHROMOSOME ABERRATION; CODON; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA DETERMINATION; ENZYME ACTIVITY; ENZYME INDUCTION; ENZYME PHOSPHORYLATION; EXON; GENE FUNCTION; GENE MUTATION; GENETIC ASSOCIATION; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; MALIGNANT PERIPHERAL NERVE SHEATH TUMOR; MASS SPECTROMETRY; MUTATIONAL ANALYSIS; NERVE SHEATH TUMOR; NEUROFIBROMATOSIS; NONSENSE MUTATION; ONCOGENE; ONCOGENE K RAS; ONCOGENE N RAS; ONCOGENE RAS; PDGFRA GENE; WESTERN BLOTTING;

EID: 84856994155     PISSN: None     EISSN: 11772727     Source Type: Journal    
DOI: 10.4137/TOG.S8830     Document Type: Article

References (31)

1. Evans DG, Baser ME, McGaughran J, Sharif S, Howard E, Moran A. Malignant peripheral nerve sheath tumours in neurofibromatosis 1. J Med Genet. 2002;39:311-4.
2. Zhu Y, Ghosh P, Charnay P, Burns DK, Parada LF. Neurofibromas in NF1: Schwann cell origin and role of tumor environment. Science. 2002; 296:920-2.
3. Carroll SL, Ratner N. How does the Schwann cell lineage form tumors in NF1? Glia. 2008;56:1590-605.
4. Courtois-Cox S, Genther Williams SM, Reczek EE, et al. A negative feedback signaling network underlies concogene-induced senescence. Cancer. 2006;10:459-72.
5. Easton DF, Ponder MA, Huson SM, Ponder BA. An analysis of variation in expression of neurofibromatosis (NF) type 1 (NF1): evidence for modifying genes. Am J Hum Genet. 1993;53:305-13.
6. Birindelli S, Perrone F, Oggionni M, et al. Rb and TP53 pathway alterations in sporadic and NF1-related malignant peripheral nerve sheath tumors. Lab Invest. 2001;81:833-44.
7. Mantripragada KK, Spurlock G, Kluwe L, et al. High-resolution DNA copy number profiling of malignant peripheral nerve sheath tumors using targeted microarray-based comparative genomic hybridization. Clin Cancer Res. 2008;14:1015-24.
8. Nielsen GP, Stemmer-Rachamimov AO, Ino Y, et al. Malignant transformation of neurofibromas in neurofibromatosis 1 is associated with CDKN2A/p16 inactivation. Am J Pathol. 1999;155:1879-84.
9. DeClue JE, Heffelfinger S, Benvenuto G, et al. Epidermal growth factor receptor expression in neurofibromatosis type 1-related tumors and NF1 animal models. J Clin Invest. 2000;105:1233-41.
10. Holtkamp N, Okuducu AF, Mucha J, et al. Mutation and expression of PDGFRA and KIT in malignant peripheral nerve sheath tumors, and its implications for imatinib sensitivity. Carcinogenesis. 2006;27:664-71.
11. Lee PR, Cohen JE, Tendi EA, et al. Transcriptional profiling in an MPNSTderived cell line and normal human Schwann cells. Neuron Glia Biol. 2004;1:135-47.
12. Miller SJ, Rangwala F, Williams J, et al. Large-scale molecular comparison of human schwann cells to malignant peripheral nerve sheath tumor cell lines and tissues. Cancer Res. 2006;66:2584-91.
13. Thomas RK, Baker AC, Debiasi RM, et al. High-throughput oncogene mutation profiling in human cancer. Nat Genet. 2007;39:347-51.
14. Reynolds JE, Fletcher JA, Lytle CH, Nie L, Morton CC, Diehl SR. Molecular characterization of a 17q11.2 translocation in a malignant schwannoma cell line. Hum Genet. 1992;90:450-6.
15. Barkan B, Starinsky S, Friedman E, Stein R, Kloog Y. The Ras inhibitor farnesylthiosalicylic acid as a potential therapy for neurofibromatosis type 1. Clin Cancer Res. 2006;12:5533-42.
16. Fieber LA, Gonzalez DM, Wallace MR, Muir D. Delayed rectifier K currents in NF1 Schwann cells. Pharmacological block inhibits proliferation. Neurobiol Dis. 2003;13:136-46.
17. Dahlberg WK, Little JB, Fletcher JA, Suit HD, Okunieff P. Radiosensitivity in vitro of human soft tissue sarcoma cell lines and skin fibroblasts derived from the same patients. Int J Radiat Biol. 1993;63:191-8.
18. Basu TN, Gutmann DH, Fletcher JA, Glover TW, Collins FS, Downward J. Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients. Nature. 1992;356:713-5.
19. Grobmyer SR, Reith JD, Shahlaee A, Bush CH, Hochwald SN. Malignant Peripheral Nerve Sheath Tumor: molecular pathogenesis and current management considerations. J Surg Oncol. 2008;97:340-9.
20. Watson MA, Perry A, Tihan T, et al. Gene expression profiling reveals unique molecular subtypes of Neurofibromatosis Type I-associated and sporadic malignant peripheral nerve sheath tumors. Brain Pathol. 2004;14:297-303.
21. Li Y, Rao PK, Wen R. Notch and Schwann cell transformation. Oncogene. 2004;23:1146-52.
22. Lopez G, Torres K, Liu J, et al. Autophagic survival in resistance to histone deacetylase inhibitors: novel strategies to treat malignant peripheral nerve sheath tumors. Cancer Res. 2011;71:185-96.
23. Forbes SA, Bindal N, Bamford S, et al. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res. 2011;39:D945-50.
24. Bottillo I, Ahlquist T, Brekke H, et al. Germline and somatic NF1 mutations in sporadic and NF1-associated malignant peripheral nerve sheath tumours. J Pathol. 2009;217:693-701.
25. Perrone F, Da Riva L, Orsenigo M, et al. PDGFRA, PDGFRB, EGFR, and downstream signaling activation in malignant peripheral nerve sheath tumor. Neuro Oncol. 2009;11:725-36.
26. Tawbi H, Thomas D, Lucas DR, et al. Epidermal growth factor receptor expression and mutational analysis in synovial sarcomas and malignant peripheral nerve sheath tumors. Oncologist. 2008;13:459-66.
27. Gill S, Stratton MR, Patterson H, et al. Detection of transforming genes by transfection of DNA from primary soft-tissue tumours. Oncogene. 1991;6: 1651-6.
28. Jin Y, Shima Y, Furu M, et al. Absence of oncogenic mutations of RAS family genes in soft tissue sarcomas of 100 Japanese patients. Anticancer Res. 2010;30:245-51.
29. Loughrey MB, Trivett M, Beshay V, et al. KIT immunohistochemistry and mutation status in gastrointestinal stromal tumours (GISTs) evaluated for treatment with imatinib. Histopathology. 2006;49:52-65.
30. Perry A, Kunz SN, Fuller CE, et al. Differential NF1, p16, and EGFR patterns by interphase cytogenetics (FISH) in malignant peripheral nerve sheath tumor (MPNST) and morphologically similar spindle cell neoplasms. J Neuropathol Exp Neurol. 2002;61:702-9.
31. Storlazzi CT, Brekke HR, Mandahl N, et al. Identification of a novel amplicon at distal 17q containing the BIRC5/SURVIVIN gene in malignant peripheral nerve sheath tumours. J Pathol. 2006;209:492-500.